Which has better earnings and valuation, ARDX or RGNX?

Ardelyx has higher revenue and earnings than REGENXBIO. Ardelyx is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ardelyx $407.32M 3.67 -$61.60M -$0.23 N/A REGENXBIO $170.44M 2.37 -$193.88M -$5.60 N/A

Is ARDX or RGNX more profitable?

Ardelyx has a net margin of -13.58% compared to REGENXBIO's net margin of -330.23%. Ardelyx's return on equity of -38.11% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -13.58% -38.11% -11.85% REGENXBIO -330.23% -232.50% -61.02%

Does the media refer more to ARDX or RGNX?

In the previous week, Ardelyx had 2 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Ardelyx and 3 mentions for REGENXBIO. Ardelyx's average media sentiment score of 0.79 beat REGENXBIO's score of 0.00 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MLTX or RGNX?

In the previous week, MoonLake Immunotherapeutics had 7 more articles in the media than REGENXBIO. MarketBeat recorded 10 mentions for MoonLake Immunotherapeutics and 3 mentions for REGENXBIO. MoonLake Immunotherapeutics' average media sentiment score of 0.27 beat REGENXBIO's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RGNX or INBX?

In the previous week, REGENXBIO had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 3 mentions for REGENXBIO and 1 mentions for Inhibrx Biosciences. REGENXBIO's average media sentiment score of 0.00 equaled Inhibrx Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PURR or RGNX?

In the previous week, Hyperliquid Strategies and Hyperliquid Strategies both had 3 articles in the media. Hyperliquid Strategies' average media sentiment score of 0.89 beat REGENXBIO's score of 0.00 indicating that Hyperliquid Strategies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, AVLN or RGNX?

Avalyn Pharma has higher earnings, but lower revenue than REGENXBIO. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A REGENXBIO $170.44M 2.37 -$193.88M -$5.60 N/A

Does the media prefer AVLN or RGNX?

In the previous week, REGENXBIO had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for REGENXBIO and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.00 equaled REGENXBIO'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

REGENXBIO (RGNX) Competitors

$7.80 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$7.95 +0.15 (+1.95%)

As of 06/18/2026 07:55 PM Eastern

Compare

RGNX vs. ARDX, MLTX, INBX, PURR, and AVLN

Should you buy REGENXBIO stock or one of its competitors? MarketBeat compares REGENXBIO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with REGENXBIO include Ardelyx (ARDX), MoonLake Immunotherapeutics (MLTX), Inhibrx Biosciences (INBX), Hyperliquid Strategies (PURR), and Avalyn Pharma (AVLN). These companies are all part of the "pharmaceutical products" industry.

How does REGENXBIO compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

In the previous week, Ardelyx had 2 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Ardelyx and 3 mentions for REGENXBIO. Ardelyx's average media sentiment score of 0.79 beat REGENXBIO's score of 0.00 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ardelyx currently has a consensus target price of $15.73, suggesting a potential upside of 159.95%. REGENXBIO has a consensus target price of $23.55, suggesting a potential upside of 201.86%. Given REGENXBIO's higher probable upside, analysts clearly believe REGENXBIO is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Ardelyx has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ardelyx has higher revenue and earnings than REGENXBIO. Ardelyx is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.67	-$61.60M	-$0.23	N/A
REGENXBIO	$170.44M	2.37	-$193.88M	-$5.60	N/A

Ardelyx has a net margin of -13.58% compared to REGENXBIO's net margin of -330.23%. Ardelyx's return on equity of -38.11% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
REGENXBIO	-330.23%	-232.50%	-61.02%

Summary

Ardelyx beats REGENXBIO on 11 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, MoonLake Immunotherapeutics had 7 more articles in the media than REGENXBIO. MarketBeat recorded 10 mentions for MoonLake Immunotherapeutics and 3 mentions for REGENXBIO. MoonLake Immunotherapeutics' average media sentiment score of 0.27 beat REGENXBIO's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MoonLake Immunotherapeutics presently has a consensus price target of $23.85, suggesting a potential upside of 24.13%. REGENXBIO has a consensus price target of $23.55, suggesting a potential upside of 201.86%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MoonLake Immunotherapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. MoonLake Immunotherapeutics' return on equity of -85.15% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
REGENXBIO	-330.23%	-232.50%	-61.02%

REGENXBIO has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
REGENXBIO	$170.44M	2.37	-$193.88M	-$5.60	N/A

Summary

MoonLake Immunotherapeutics beats REGENXBIO on 7 of the 13 factors compared between the two stocks.

How does REGENXBIO compare to Inhibrx Biosciences?

REGENXBIO (NASDAQ:RGNX) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, REGENXBIO had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 3 mentions for REGENXBIO and 1 mentions for Inhibrx Biosciences. REGENXBIO's average media sentiment score of 0.00 equaled Inhibrx Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inhibrx Biosciences has lower revenue, but higher earnings than REGENXBIO. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.37	-$193.88M	-$5.60	N/A
Inhibrx Biosciences	$1.30M	1,050.03	-$140.05M	-$8.39	N/A

REGENXBIO currently has a consensus price target of $23.55, suggesting a potential upside of 201.86%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 61.20%. Given REGENXBIO's stronger consensus rating and higher possible upside, equities analysts clearly believe REGENXBIO is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Inhibrx Biosciences has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. REGENXBIO's return on equity of -232.50% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

REGENXBIO has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.33, meaning that its share price is 233% more volatile than the broader market.

Summary

REGENXBIO beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and REGENXBIO (NASDAQ:RGNX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Hyperliquid Strategies has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

In the previous week, Hyperliquid Strategies and Hyperliquid Strategies both had 3 articles in the media. Hyperliquid Strategies' average media sentiment score of 0.89 beat REGENXBIO's score of 0.00 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hyperliquid Strategies has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Hyperliquid Strategies' return on equity of -56.04% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
REGENXBIO	-330.23%	-232.50%	-61.02%

Hyperliquid Strategies has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,340.50	-$16.01M	-$7.37	N/A
REGENXBIO	$170.44M	2.37	-$193.88M	-$5.60	N/A

Hyperliquid Strategies currently has a consensus target price of $9.25, indicating a potential downside of 0.32%. REGENXBIO has a consensus target price of $23.55, indicating a potential upside of 201.86%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts plainly believe REGENXBIO is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Hyperliquid Strategies beats REGENXBIO on 8 of the 15 factors compared between the two stocks.

How does REGENXBIO compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and REGENXBIO (NASDAQ:RGNX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, REGENXBIO had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for REGENXBIO and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.00 equaled REGENXBIO'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalyn Pharma currently has a consensus price target of $59.00, suggesting a potential upside of 87.60%. REGENXBIO has a consensus price target of $23.55, suggesting a potential upside of 201.86%. Given REGENXBIO's higher probable upside, analysts clearly believe REGENXBIO is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Avalyn Pharma has higher earnings, but lower revenue than REGENXBIO.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
REGENXBIO	$170.44M	2.37	-$193.88M	-$5.60	N/A

Avalyn Pharma has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Avalyn Pharma's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
REGENXBIO	-330.23%	-232.50%	-61.02%

Summary

REGENXBIO beats Avalyn Pharma on 6 of the 11 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGNX vs. The Competition

Export

Metric	REGENXBIO	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$403.24M	$3.41B	$6.65B	$12.60B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-1.39	19.73	24.75	24.42
Price / Sales	2.37	320.32	529.30	111.09
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	3.84	8.15	10.81	6.60
Net Income	-$193.88M	$23.91M	$3.57B	$337.10M
7 Day Performance	17.12%	2.57%	0.72%	0.83%
1 Month Performance	15.56%	0.69%	0.41%	2.25%
1 Year Performance	-7.47%	55.09%	29.34%	36.14%

REGENXBIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGNX REGENXBIO	2.524 of 5 stars	$7.80 flat	$23.55 +201.9%	-7.5%	$403.24M	$170.44M	N/A	370	News Coverage Gap Up High Trading Volume
ARDX Ardelyx	2.8418 of 5 stars	$5.69 -0.1%	$15.70 +176.2%	+69.9%	$1.41B	$407.32M	N/A	90	News Coverage Positive News Analyst Forecast
MLTX MoonLake Immunotherapeutics	2.7038 of 5 stars	$18.87 +1.0%	$23.85 +26.4%	-55.8%	$1.40B	N/A	N/A	2	News Coverage Insider Trade
INBX Inhibrx Biosciences	2.0088 of 5 stars	$93.79 +1.7%	$150.00 +59.9%	+523.2%	$1.38B	$1.30M	N/A	166	Analyst Forecast Gap Up
PURR Hyperliquid Strategies	1.8186 of 5 stars	$9.52 +9.4%	$9.25 -2.8%	N/A	$1.38B	$1M	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGNX) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Competitors

RGNX vs. ARDX, MLTX, INBX, PURR, and AVLN

How does REGENXBIO compare to Ardelyx?

Summary

How does REGENXBIO compare to MoonLake Immunotherapeutics?

Summary

How does REGENXBIO compare to Inhibrx Biosciences?

Summary

How does REGENXBIO compare to Hyperliquid Strategies?

Summary

How does REGENXBIO compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

REGENXBIO (RGNX) Competitors

RGNX vs. ARDX, MLTX, INBX, PURR, and AVLN

How does REGENXBIO compare to Ardelyx?

Does the media refer more to ARDX or RGNX?

Do analysts prefer ARDX or RGNX?

Which has more volatility and risk, ARDX or RGNX?

Do institutionals and insiders hold more shares of ARDX or RGNX?

Which has better earnings and valuation, ARDX or RGNX?

Is ARDX or RGNX more profitable?

Summary

How does REGENXBIO compare to MoonLake Immunotherapeutics?

Does the media refer more to MLTX or RGNX?

Do analysts recommend MLTX or RGNX?

Do institutionals and insiders have more ownership in MLTX or RGNX?

Which has more risk and volatility, MLTX or RGNX?

Is MLTX or RGNX more profitable?

Which has stronger valuation and earnings, MLTX or RGNX?

Summary

How does REGENXBIO compare to Inhibrx Biosciences?

Does the media prefer RGNX or INBX?

Which has preferable earnings & valuation, RGNX or INBX?

Do analysts rate RGNX or INBX?

Do insiders & institutionals hold more shares of RGNX or INBX?

Is RGNX or INBX more profitable?

Which has more risk and volatility, RGNX or INBX?

Summary

How does REGENXBIO compare to Hyperliquid Strategies?

Which has more risk & volatility, PURR or RGNX?

Does the media favor PURR or RGNX?

Do institutionals and insiders hold more shares of PURR or RGNX?

Is PURR or RGNX more profitable?

Which has preferable valuation & earnings, PURR or RGNX?

Do analysts prefer PURR or RGNX?

Summary

How does REGENXBIO compare to Avalyn Pharma?

Do institutionals & insiders believe in AVLN or RGNX?

Does the media prefer AVLN or RGNX?

Do analysts rate AVLN or RGNX?

Which has higher earnings and valuation, AVLN or RGNX?

Is AVLN or RGNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools